Immunoregulatory Effects of Adsorptive Granulocyte and Monocyte Apheresis in Patients with Drug Refractory Crohn's Disease

Therapeutic Apheresis and Dialysis

Volumn 15, Issue 4, 2011, Pages 367-373

  Nagase, Kazuko ^a   Fukunaga, Ken ^a   Kashiwamura, Shinichiro ^a   Kono, Tomoaki ^a   Kamikozuru, Koji ^a   Yokoyama, Yoko ^a   Hida, Nobuyuki ^a   Ohda, Yoshio ^a   Takeda, Naohisa ^a   Yoshida, Koji ^a   Iimuro, Masaki ^a   Kikuyama, Risa ^a,b   Kato, Kyoichi ^a   Miwa, Hiroto ^a   Matsumoto, Takayuki ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adsorptive granulocyte and monocyte apheresis; Crohn's disease; Regulatory T cell; TGF 1; Th1 Th2 balamce

Indexed keywords

AZATHIOPRINE; CHEMOKINE; CYTOKINE; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; INTERLEUKIN 9; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA1;

ADOLESCENT; ADULT; AGED; APHERESIS; ARTICLE; BLOOD FLOW; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRANULOCYTE MONOCYTE APHERESIS; HEMOFILTRATION; HUMAN; IMMUNOREGULATION; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; REGULATORY T LYMPHOCYTE; SCHOOL CHILD; TH1 CELL; TH2 CELL; VOLUNTEER;

ADULT; BLOOD COMPONENT REMOVAL; CHEMOKINES; CROHN DISEASE; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GRANULOCYTES; HUMANS; INFLAMMATION MEDIATORS; JAPAN; MALE; MONOCYTES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

EID: 80052019634     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2011.00970.x     Document Type: Article

References (26)

1. Targan SR, Hanauer SB, van Deventer SJH etal. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997;337:1029-35.
2. Fiorino G, Rovida S, Correale C, Malesci A, Danese S. Emerging biologics in the treatment of inflammatory bowel diseasewhat is around the corner? Curr Drug Targets 2010;11:249-60.
3. Hanauer SB, Feagan BG, Lichtenstein GR etal. Maintenance infliximab for Crohn's diseasethe ACCENT I randomised trial. Lancet 2002;359:1541-9.
4. Hanai H, Iida T, Takeuchi K etal. Adsorptive depletion of elevated proinflammatory CD14+CD16+DR++ monocytes in patients with inflammatory bowel disease. Am J Gastroenterol 2008;103:1210-6.
5. Fukuda Y, Matsui T, Suzuki Y etal. Adsorptive granulocyte and monocyte apheresis for refractory Crohn's diseasean open multicenter prospective study. J Gastroenterol 2004;39:1158-64.
6. Cancer Warnings Required for TNF Blockers. FDA news release, The U.S. Food and Drug Administration, 4 August 2009. [Accessed 22 Oct 2009.] Available from URL
7. +, in patients with ulcerative colitis during active and quiescent disease. Clin Exp Immunol 2009;156:320-7.
8. Winship DH, Summers RW, Singleton JW etal. National cooperative Crohn's disease studystudy design and conduct of the study. Gastroenterology 1979;77:829-42.
9. Matsui T, Nishimura T, Matake H, Ohta T, Sakurai T, Yao T. Granulocytapheresis for Crohn's diseasea report on seven refractory patients. Am J Gastroenterol 2003;98:511-2.
10. Shimoyama T, Sawada K, Hiwatashi N etal. Safety and efficacy of granulocytes and monocyte adsorption apheresis in patients with active ulcerative colitisa multicenter study. J Clin Apher 2001;16:1-9.
11. Nagase K, Fukunaga K, Ohnishi K, Kusaka T, Matoba Y, Sawada K. Detection of specific IgE antibodies to Nafamostat mesilate as an induction of possible adverse effects of leukocytapheresis using Nafamostat mesilate as anticoagulant. Ther Apher Dial 2004;8:45-51.
12. Kato K, Fukunaga K, Kamikozuru K etal. Infliximab therapy impacts on the peripheral immune-system of immunomodulator and corticosteroid naïve patients with Crohn's disease. Gut Liver 2011; 5:37-45.
13. Niu X, Miasnikova GY, Sergueeva AI etal. Altered cytokine profiles in patients with Chuvash polycythemia. Am J Hematol 2009;84:74-8.
14. Fiocchi C. Inflammatory bowel diseaseetiology and pathogenesis. Gastroenterology 1998;115:182-205.
15. 3 and its ligands. J Biol Chem 2003;278:289-95.
16. Oki M, Ohtani H, Kinouchi Y etal. Accumulation of CCR5+ T cells around RANTES+ granulomas in Chohn's diseasea pivotal site of Th1-shifted immune response? Lab Invest 2005;85:137-45.
17. Freeman HJ. Granuloma-positive Crohn's disease. Can J Gastroenterol 2007;21:583-7.
18. Maul J, Loddenkemper C, Mundt P etal. Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology 2005;128:1868-78.
19. Powrie F, Read S, Mottet C etal. Control of immune pathology by regulatory T cells. Novartis Found Symp 2003;252:92-8.
20. Liu H, Hu B, Xu D etal. CD4+CD25+ regulatory T cells cure murine colitisthe role of IL-10, TGF-beta, and CTLA4. J Immunol 2003;171:5012-7.
21. Baecher-Allan C, Brown JA, Freeman GJ etal. CD4+CD25high regulatory cells in human peripheral blood. J Immunol 2001;167:1245-53.
22. Bettelli E, Carrier Y, Gao W etal. Reciprocal developmental pathways for the generation of pathogenic effecter TH17 and regulatory T cells. Nature 2006;441:235-8.
23. Gorelik L, Constant S, Flavell RA. Mechanism of transforming growth factor beta-induced inhibition on T-helper type 1 differentiation. J Exp Med 2002;195:1499-505.
24. Farrel RJ, Alsahli M, Jeen YT etal. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's diseasea randomized controlled trial. Gastroenterology 2003;124:917-24.
25. Fukunaga K, Yokoyama Y, Kamikozuru K etal. Selective depletion of peripheral granulocyte/monocyte enhances the efficacy of scheduled maintenance infliximab in Crohn's disease. J Clin Apher 2010;25:226-8.
26. Sakuraba A, Motoya S, Watanabe K etal. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol 2009;104:2990-5.